Phio Pharmaceuticals Corp (PHIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 21,031 | 5,382 | 8,490 | 11,831 | 24,107 |
| TOTAL | $21,476 | $5,736 | $9,322 | $12,446 | $24,727 |
| Non-Current Assets | |||||
| PPE Net | 11 | 2 | 6 | 183 | 133 |
| Other Non-Current Assets | 0 | 0 | 36 | 185 | 310 |
| TOTAL | $11 | $2 | $42 | $368 | $443 |
| Total Assets | $21,487 | $5,738 | $9,364 | $12,814 | $25,170 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 435 | 253 | 657 | 779 | 283 |
| Accrued Expenses | 905 | 762 | 942 | 1,025 | 2,660 |
| TOTAL | $1,340 | $1,015 | $1,634 | $1,939 | $3,068 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 0 | 37 | 170 |
| TOTAL | $N/A | $N/A | $N/A | $37 | $170 |
| Total Liabilities | $1,340 | $1,015 | $1,634 | $1,976 | $3,238 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 11,617 | 4,778 | 510 | 128 | 125 |
| Common Shares | 1 | N/A | N/A | N/A | N/A |
| Retained earnings | -155,054 | -146,356 | -139,206 | -128,380 | -116,900 |
| TOTAL | $20,147 | $4,723 | $7,730 | $10,838 | $21,932 |
| Total Liabilities And Equity | $21,487 | $5,738 | $9,364 | $12,814 | $25,170 |